Reig Jofre and Stada Increase Production for the Sale of a Drug Against Parkinson’s Disease

Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company Reig Jofre, and Stada have signed an agreement to expand production capacity for a drug used to treat advanced Parkinson’s disease. Since the launch of the infusion pump-based combination drug in 2020, Bioglan has delivered around 250,000 doses across 100 batches, meeting the needs of patients in the initial launch countries.

In order to meet the growing demand for the therapy as Stada introduces it in other European countries over the coming months, the companies have agreed to build a new manufacturing facility in Malmö, Sweden. The investment in this expansion, which adds a sixth semi-solid production line, amounts to more than three million euros, Reig Jofre said in a statement.

This line will manufacture a patented pharmaceutical gel formulation containing a combination of levodopa, carbidopa, and entacapone in a 47-milliliter pre-filled cartridge for continuous infusion into the small intestine via a discrete, lightweight, and portable pump weighing 134 grams. This infusion pump is currently prescribed in patients with late-stage Parkinson’s disease who experience debilitating motor symptoms that can no longer be treated with oral medication.

If you want to find more details about the partnership between Reig Jofre and Stada and to read the latest business news in the world, download for free our companion app.

Reig Jofre achieved a profit of $5.8 million (€5.1 million) between January and September 2021, down 3.8%

Following initial launches in the Nordic countries, the therapy has already been approved in several European countries and Stada is currently marketing it in Germany, Austria, and Slovenia, with launches in additional European and selected international markets scheduled for the near future.

Simon Björklund, CEO of Bioglan, comments that “our expertise in developing and producing semi-solid formulations, usually for topical use, has enabled us to solve the need to make a continuously infused intra-intestinal gel available to the market.”

Robert Wood, CEO of Stada’s Britannia Pharmaceuticals subsidiary, says, “We believe this infusion formulation will have positive clinical benefits for patients who need a continuous, device-assisted form of therapy that can resolve untreatable motor fluctuations and improve their quality of life.”

Reig Jofre achieved a profit of $5.8 million (€5.1 million) between January and September 2021, down 3.8% compared with the results obtained in the same period of 2020. The Spanish drugmaker managed to increase revenue figures due to the recovery of prescription and consumer healthcare products compared to 2020 when sales were driven by Covid-19-linked essential medicines and disinfection products. At the end of September, the listed company posted $196.5 million (€173 million) in sales, 2% more than in the same period of the previous year.

__

(Featured image by pasja1000 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.